Cocrystal Pharma Files 8-K

Ticker: COCP · Form: 8-K · Filed: May 29, 2025 · CIK: 1412486

Cocrystal Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type8-K
Filed DateMay 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Cocrystal Pharma filed a standard 8-K, no major news.

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on May 29, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates routine corporate reporting by Cocrystal Pharma, Inc. to the SEC, providing transparency on their regulatory and financial disclosures.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of May 29, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is May 29, 2025.

In which U.S. state is Cocrystal Pharma, Inc. incorporated?

Cocrystal Pharma, Inc. is incorporated in Delaware.

What is the SEC file number for Cocrystal Pharma, Inc.?

The SEC file number for Cocrystal Pharma, Inc. is 001-38418.

What is the principal executive office address for Cocrystal Pharma, Inc.?

The principal executive office address is 19805 N. Creek Parkway, Bothell, WA 98011.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding Cocrystal Pharma, Inc. (COCP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing